Orchestra BioMed (OBIO) Expected to Announce Quarterly Earnings on Tuesday

Orchestra BioMed (NASDAQ:OBIO) is projected to issue its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Orchestra BioMed to announce earnings of ($0.35) per share and revenue of $0.1380 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. On average, analysts expect Orchestra BioMed to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orchestra BioMed Trading Up 2.3%

Shares of NASDAQ OBIO traded up $0.10 during trading hours on Tuesday, hitting $4.21. The company’s stock had a trading volume of 35,179 shares, compared to its average volume of 254,961. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03. The stock has a market cap of $252.39 million, a price-to-earnings ratio of -4.35 and a beta of 0.50. Orchestra BioMed has a 12 month low of $2.20 and a 12 month high of $5.42. The business has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $4.10.

Insider Buying and Selling at Orchestra BioMed

In other news, Director Eric S. Fain bought 20,000 shares of Orchestra BioMed stock in a transaction on Thursday, May 14th. The shares were purchased at an average price of $4.13 per share, for a total transaction of $82,600.00. Following the acquisition, the director owned 91,709 shares of the company’s stock, valued at approximately $378,758.17. The trade was a 27.89% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jason Aryeh bought 8,971 shares of the firm’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average cost of $3.90 per share, with a total value of $34,986.90. Following the transaction, the director directly owned 117,453 shares in the company, valued at approximately $458,066.70. This represents a 8.27% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 39,636 shares of company stock valued at $158,081. 7.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Orchestra BioMed

A number of institutional investors have recently added to or reduced their stakes in the company. Alyeska Investment Group L.P. purchased a new position in Orchestra BioMed during the third quarter valued at $3,386,000. Pathstone Holdings LLC bought a new stake in shares of Orchestra BioMed during the 3rd quarter valued at $2,495,000. Vanguard Group Inc. grew its position in shares of Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock worth $3,675,000 after buying an additional 324,558 shares during the period. Marshall Wace LLP purchased a new stake in shares of Orchestra BioMed in the 4th quarter worth about $712,000. Finally, Goldman Sachs Group Inc. increased its stake in shares of Orchestra BioMed by 467.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 134,073 shares of the company’s stock worth $556,000 after acquiring an additional 110,443 shares in the last quarter. Institutional investors own 53.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on OBIO shares. B. Riley Financial dropped their price objective on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a report on Thursday, May 14th. Barclays raised their price target on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Orchestra BioMed in a report on Friday, July 17th. Finally, Wall Street Zen downgraded shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $13.60.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical?stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high?unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early? and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.